Imagion Biosystems Limited advises that the 200,000 Performance Rights issued to Directors of the Company under the Company Long-term Incentive Plan on 14 June 2018, and approved by shareholders at the Company’s Annual General Meeting held on 31 May 2018, have passed the continuous employment vesting condition and have now vested. Accordingly, the Company has today issued 200,000 Fully Paid Ordinary Shares to the Directors as approved by shareholders at the Annual General Meeting held on 31 May 2018.
Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer
MELBOURNE – Imagion Biosystems (Company) (ASX : IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to announce